{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:32:04Z","timestamp":1790818324839,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The medical treatment of fistulizing Crohn\u2019s disease (CD) remains a challenge to clinicians. Over the last 20 years, biologic therapies have been the mainstay of medical treatment of fistulizing CD. The purpose of this study is to compare the efficacy of biologic therapies in inducing response and remission in fistulizing CD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a systematic review of the EMBASE, MEDLINE, and Cochrane Central databases from inception to December 2021. Inclusion criteria were any randomized controlled trials (RCTs) that evaluated the efficacy of biologic therapies against an active comparator or placebo for induction of response or remission in adults with fistulizing CD. The proportion of patients with fistula response or remission, as defined by each clinical trial, was our primary study outcome. A Bayesian random-effects network meta-analysis was used to measure treatment effects and results were reported as odds ratio (OR) and 95% confidence interval (CI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In our analysis, 10 studies were included, and all were RCTs. Infliximab was superior to adalimumab in inducing response (OR, 0.24; 95% CI, 0.06-0.99) but not in inducing remission (OR, 0.31; 95% CI, 0.04-2.27). Tumor necrosis factor antagonists were superior to placebo in the induction of response (OR, 0.51; 95% CI, 0.35-0.750) and remission (OR, 0.36; 95% CI, 0.22-0.58). Infliximab was superior to placebo in inducing response (OR, 0.36; 95% CI, 0.17-0.75) and remission (OR, 0.17; 95% CI, 0.03-0.87). Ustekinumab was superior to placebo in inducing response (OR, 0.48; 95% CI, 0.26-0.860) but not in inducing remission (OR, 0.50; 95% CI, 0.13-1.93). When comparing biologic therapies against each other, there was no statistical difference in inducing remission. Vedolizumab was not superior to placebo in inducing remission (OR, 0.32; 95% CI, 0.04-2.29). Certolizumab was not superior to placebo in inducing response (OR, 0.78; 95% CI, 0.40-1.55) or remission (OR, 0.78; 95% CI, 0.40-1.55).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Tumor necrosis factor antagonists are effective in inducing response and remission in fistulizing CD. Infliximab was superior to adalimumab for inducing response but not for inducing remission. Ustekinumab is effective in the induction of response but not in the induction of remission. When compared against each other, biologic therapies showed no significant difference in the induction of remission. Based on the available data, infliximab is the preferred first-line treatment. As for other biologics, the limited published data do not allow us to make firm recommendations. This study supports current practice and emphasizes the need for dedicated RCTs to evaluate the efficacy of biologic therapies in fistulizing CD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izac103","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T14:50:46Z","timestamp":1653317446000},"page":"367-375","source":"Crossref","is-referenced-by-count":50,"title":["Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn\u2019s Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-3956","authenticated-orcid":false,"given":"Mohammad","family":"Shehab","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Mubarak Alkabeer University Hospital , Aljabreyah , Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4020-5978","authenticated-orcid":false,"given":"Fatema","family":"Alrashed","sequence":"additional","affiliation":[{"name":"Department of Public Health, Massachusetts College of Pharmacy and Health Sciences , Boston, MA , USA"},{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Health Science Center, Kuwait University , Jabirya , Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-7501","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Heron","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Maisonneuve-Rosemont Hospital, University of Montreal , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0646-3439","authenticated-orcid":false,"given":"Sophie","family":"Restellini","sequence":"additional","affiliation":[{"name":"Division of Qastroenterology, Department of Medicine, University Hospital of Geneva , Geneva , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2610-1910","authenticated-orcid":false,"given":"Talat","family":"Bessissow","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Montreal General Hospital, McGill University Health Center , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"issue":"5","key":"2023102516100252500_CIT0001","first-page":"1542","article-title":"Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn\u2019s disease: ENTERPRISE study","volume":"21","author":"Schwartz","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"7","key":"2023102516100252500_CIT0002","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/DCR.0b013e31825228b0","article-title":"The spectrum of perianal crohn\u2019s disease in a population-based cohort","volume":"55","author":"Eglinton","year":"2012","journal-title":"Dis Colon Rectum."},{"issue":"1","key":"2023102516100252500_CIT0003","first-page":"233","article-title":"American Gastroenterological Association medical position statement: diagnosis and care of patients with anal fissure","volume":"124","year":"2003","journal-title":"Gastroenterology"},{"issue":"1","key":"2023102516100252500_CIT0004","first-page":"33","article-title":"Management of complex perianal crohn\u2019s disease","volume":"30","author":"Aguilera-Castro","year":"2017","journal-title":"Ann Gastroenterol"},{"issue":"1","key":"2023102516100252500_CIT0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10151-012-0890-x","article-title":"Sexual function and quality of life after surgical treatment for anal fistulas in Crohn\u2019s disease","volume":"17","author":"Riss","year":"2013","journal-title":"Tech Coloproctol."},{"issue":"8","key":"2023102516100252500_CIT0006","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cgh.2012.12.042","article-title":"Long-term outcome of perianal fistulizing crohn\u2019s disease treated with infliximab","volume":"11","author":"Bouguen","year":"2013","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"2","key":"2023102516100252500_CIT0007","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/gast.1999.0029900429","article-title":"Successful management of Crohn\u2019s disease of the ileoanal pouch with infliximab","volume":"117","author":"Ricart","year":"1999","journal-title":"Gastroenterology"},{"issue":"1","key":"2023102516100252500_CIT0008","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MCG.0000000000000169","article-title":"Effectiveness of adalimumab in perianal fistulas in Crohn\u2019s disease patients naive to anti-TNF therapy","volume":"49","author":"Casta\u00f1o-Milla","year":"2015","journal-title":"J Clin Gastroenterol."},{"issue":"9","key":"2023102516100252500_CIT0009","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulising Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med."},{"issue":"10","key":"2023102516100252500_CIT0010","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/MCG.0b013e3181986917","article-title":"Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing crohn\u2019s disease","volume":"43","author":"Taxonera","year":"2009","journal-title":"J Clin Gastroenterol."},{"key":"2023102516100252500_CIT0011","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"15","key":"2023102516100252500_CIT0012","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2023102516100252500_CIT0013","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2023102516100252500_CIT0014","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"issue":"18","key":"2023102516100252500_CIT0015","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med."},{"issue":"10","key":"2023102516100252500_CIT0016","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1111\/j.1572-0241.2003.07675.x","article-title":"Management of Crohn\u2019s disease of the ileoanal pouch with infliximab","volume":"98","author":"Colombel","year":"2003","journal-title":"Am J Gastroenterol."},{"issue":"8","key":"2023102516100252500_CIT0017","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1365-2036.2006.02878.x","article-title":"Maintenance infliximab does not result in increased abscess development in fistulizing Crohn\u2019s disease: results from the ACCENT II study","volume":"23","author":"Sands","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"2023102516100252500_CIT0018","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"issue":"1","key":"2023102516100252500_CIT0019","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn\u2019s disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J Crohn\u2019s Colitis."},{"issue":"5","key":"2023102516100252500_CIT0020","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","article-title":"Efficacy of vedolizumab in fistulising Crohn\u2019s disease: exploratory analyses of data from GEMINI 2","volume":"12","author":"Feagan","year":"2018","journal-title":"J Crohn\u2019s Colitis."},{"issue":"5","key":"2023102516100252500_CIT0021","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2016","journal-title":"Gut"},{"issue":"5","key":"2023102516100252500_CIT0022","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cgh.2021.09.028","article-title":"Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn\u2019s disease: ENTERPRISE study","volume":"20","author":"Schwartz","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"11","key":"2023102516100252500_CIT0023","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.14309\/ajg.0000000000000810","article-title":"Ustekinumab for perianal Crohn\u2019s disease: the BioLAP multicenter study from the GETAID","volume":"115","author":"Chapuis-Biron","year":"2020","journal-title":"Am J Gastroenterol."},{"issue":"20","key":"2023102516100252500_CIT0024","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"issue":"3","key":"2023102516100252500_CIT0025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1","key":"2023102516100252500_CIT0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/00365521.2020.1854848","article-title":"Efficacy of ustekinumab for active perianal fistulizing Crohn\u2019s disease: a systematic review and meta-analysis of the current literature","volume":"56","author":"Attauabi","year":"2021","journal-title":"Scand J Gastroenterol."},{"issue":"suppl 3","key":"2023102516100252500_CIT0027","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"issue":"4","key":"2023102516100252500_CIT0028","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jcag\/gwy047","article-title":"Clinical practice guideline for the medical management of perianal fistulizing Crohn\u2019s disease: the Toronto consensus","volume":"1","author":"Steinhart","year":"2018","journal-title":"J Can Assoc Gastroenterol."},{"issue":"6","key":"2023102516100252500_CIT0029","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"7","key":"2023102516100252500_CIT0030","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/apt.12906","article-title":"Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn\u2019s disease","volume":"40","author":"Yassin","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"issue":"2","key":"2023102516100252500_CIT0031","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/gutjnl-2013-304488","article-title":"Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn\u2019s disease: a randomised, double-blind, placebo controlled trial (ADAFI)","volume":"63","author":"Dewint","year":"2014","journal-title":"Gut"},{"issue":"5","key":"2023102516100252500_CIT0032","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.cgh.2017.08.025","article-title":"Heterogeneity in definitions of endpoints for clinical trials of ulcerative colitis: a systematic review for development of a core outcome set","volume":"16","author":"Ma","year":"2018","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"9","key":"2023102516100252500_CIT0033","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.cgh.2018.02.051","article-title":"Heterogeneity in definitions of efficacy and safety endpoints for clinical trials of Crohn\u2019s disease: a systematic review","volume":"16","author":"Ma","year":"2018","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac103\/43797074\/izac103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/3\/367\/52523915\/izac103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/29\/3\/367\/52523915\/izac103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T16:10:34Z","timestamp":1698250234000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/29\/3\/367\/6590761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,5,23]]},"published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac103","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,5,23]]}}}